H.C. Wainwright Remains a Hold on Alaunos Therapeutics (TCRT)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Alaunos Therapeutics (TCRTResearch Report). The company’s shares closed yesterday at $2.91.

Ramakanth covers the Healthcare sector, focusing on stocks such as Mediwound, ImmunoGen, and Precigen. According to TipRanks, Ramakanth has an average return of -8.6% and a 31.18% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alaunos Therapeutics with a $3.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

TCRT market cap is currently $629.1M and has a P/E ratio of -11.52.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Read More on TCRT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More